Letter. Intensity-modulated radiotherapy for the treatment of breast cancer [PDF]
, 2013 In the systematic review of intensity-modulated radiotherapy (IMRT) in the treatment of breast cancer reported in Clinical Oncology by Dayes and colleagues [1], the only prospective randomised clinical trial (n = 306) testing forward-planned IMRT to have
Coles, C.E. +3 more
core +1 more source
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
Molecular Oncology, EarlyView.In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi +3 more
wiley +1 more source
Training health visitors in cognitive behavioural and person-centred approaches for depression in postnatal women as part of a cluster randomised trial and economic evaluation in primary care: the PoNDER trial [PDF]
, 2011 Aim: This paper aims to describe the training preparation for health visitors who took part in the intervention arm of a cluster randomised controlled trial and economic evaluation of training for health visitors – the POstNatal Depression Economic ...
Barkham, M. +5 more
core +1 more source
Clinical trial design and new therapies for pulmonary arterial hypertension
European Respiratory Journal, 2019 Until 20 years ago the treatment of pulmonary arterial hypertension (PAH) was based on case reports and small series, and was largely ineffectual. As a deeper understanding of the pathogenesis and pathophysiology of PAH evolved over the subsequent two ...
O. Sitbon +9 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker +14 more
wiley +1 more source
The Role of Functional, Social, and Mobility Dynamics in Facilitating Older African Americans Participation in Clinical Research [PDF]
, 2017 Purpose: Older African Americans experience disproportionately higher incidence of morbidity and mortality related to chronic and infectious diseases, yet are significantly underrepresented in clinical research compared to other racial and ethnic groups.
Frew, Paula M. +4 more
core +1 more source
Rethinking the therapeutic misconception: social justice, patient advocacy, and cancer clinical trial recruitment in the US safety net. [PDF]
, 2014 BackgroundApproximately 20% of adult cancer patients are eligible to participate in a clinical trial, but only 2.5-9% do so. Accrual is even less for minority and medically underserved populations. As a result, critical life-saving treatments and quality
Burke, Nancy J
core +3 more sources
Molecular Oncology, EarlyView.In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen +13 more
wiley +1 more source
Adaptive designs in clinical trials: why use them, and how to run and report them [PDF]
, 2018 Adaptive designs can make clinical trials more flexible by utilising results accumulating in the trial to modify the trial’s course in accordance with pre-specified rules.
Bedding, Alun W +15 more
core +9 more sources
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients
Molecular Oncology, EarlyView.Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha +6 more
wiley +1 more source